Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 3Terminated 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma 1Hematologic Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Antibodies, Bispecific × Clear all
NCT05293912 2025-03-18

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Hangzhou Sumgen Biotech Co., Ltd.

Phase 1 Terminated
2 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

NCT03035253 2020-08-11

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Mereo BioPharma

Phase 1 Terminated
16 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡